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INTRODUCTION 
NECESSITY IS THE MOTHER OF INVENTION 
Humans in this modern world have made numerous inventions for their 
survival and existence. Organophosphorous compounds are one of those creations. 
Being developed as pesticides, now they form important ingredient of   weapons 
of mass destruction. In spite of increased dividends in food production and vector 
control, these compounds have resulted in serious ill effects to man and his 
ecosystem.  
 More than 225 groups of organophosphorous pesticides are being marketed 
world wide.  These pesticides are misused as an important commodity for 
deliberate self harm in developing world. Self poisoning with agricultural 
pesticides is an important cause of mortality in many rural areas(1) Case fatality 
rate of  organophosphates may exceed 60% in third world countries.(1). They form 
the major group of suicidal poisoning in developing countries because of their 
easy availability, cheap cost and their toxic nature. The developed nations have 
also renewed their interest in these compounds because of its potency as weapons 
of mass destruction.   In this current scenario medical management of acute opc 
poisoning is having lacunae in evidence based treatment protocols and research 
tools that would reduce mortality. This calls for an urgent comprehensive analysis 
of opc poisoning to promote a preventive, educational and management 
programme in countries like India where economy is predominantly based upon 
agricultural sector . (1) 
 REVIEW OF LITERATURE 
HISTORY 
            In the era of industrial revolution many organophosphorous compounds 
were synthesized. As early 1854 CLERMONT prepared tetra ethyl pyrophosphate 
(TEPP) OPC made its mark in modern chemistry when LANGE and KRUEGER 
recorded the synthesis of di-methyl di-ethyl phosphor fluoridates in 1932(2). They 
observed that inhalation of these compounds produced blurring of vision and 
choking sensation.  But opc as pesticides were produced by a group of German 
scientists led by Gerhard Schrader, FarbenFebriken and Bayer AG 1937.The 
possibilities of potential chemical warfare with these agents were explored by 
Nazis in World War II. Indeed Sarin (isopropyl methyl phosphono fluoridate) was 
used by Iraq against Kurdish rebels in villages of north IRAQ. (3)The residues of 
Sarin were still found in analysis of the soil. In 1944 SCHRADER synthesized 
parathion which was widely used as a pesticide.In1870 FRASER developed 
atropine as an antidote to physostigmine. COLLOMP in 1949 experimented 
atropine against muscarinic effects of nerve gas .In 1955 Davies introduced 
oximes and I.B WILSON confirmed its usefulness in opc acute poisoning 
.NAMBA for the first time used pralidoxime in his victims of opc poisoning in 
1956. Lallement studied GK-11 an anti Glutamimmetic drug as a neuro protective 
agent in OPC in 1997.In 1998 adenosine receptor antagonist role was studied in 
opc necessitating further studies.  
 TABLE 1 CLASSIFICATION AND THEIR STRUCTURE 
Sl. No. Common Name Trade Name 
1. Acephate  Asataf, Orthene, Starthene 
2. Chlorpyrifos Dursban, Durmet, Lorsban 
3. Dichlorvas Noovan 
4. Dimethoate Rogar, Tara 909, Fosfamid 
5. Fenitrothian Surmunion, Nitrophos  
6. Fenthion Baycid, Baytex 
7. Malathion Cythion, Chemathion 
8. Methyl Parathion Metacid, Folitav, Paramox, 
Metaphos 
9. Monocrotophos Monocron, Nivacron, Luphos 
10. Phorate Thimet, Pempart 
11. Parathion  Folidol, Ekatox 
12. Phosphomidon Dimecron, Famfos 
13. Quinalphos  Ekalux 
 
GENERAL CHEMICAL STRUCTURE  
Organophosphorous compounds are basically esters of phosphoric acid or 
of   phosphorothioic acids (4).The R denotes either ethyl or methyl group. The 
organothiophosphates which contains double bonded sulphur group are converted 
into organophosphates in the liver.Phosphonate contains an alkyl(R-) in place of 
one alkoxy group (RO-). The X is called the leaving group and is the principal 
metabolite for species identification. (5). 
 RO  S(or O)  
   P 
   RO  X (Leaving Group) 
 
 
 
KINETICS 
 The kinetics of each group are highly dependent upon many factors such 
as route of administration such as ingestion, injection ,inhalation ,transdermal and 
transmucosal exposure, distance from target organs, local versus systemic 
metabolism and activation, route of elimination, endogenous hydrolysis and 
consumption of the compound  by non specific esterases. Each group has its 
chemical structure ,R- groups attached to the sulphur, carbon, or phosphorus 
entity, tightness of the bond to the central atom and the inherent affinity to 
cholinesterase.(6) After absorption the chemicals are equally distributed in all 
tissues but predominantly in liver and the renal. Lipophilic compounds reach 
maximum concentration in neural and other lipid rich tissues. Plasma half life after 
single dose administration depends upon the type of opc and route of exposure and 
it may range from few minutes to few hours. Metabolism occurs mainly by three 
ways namely oxidation, hydrolysis by esterases and transfer of portion of molecule 
to glutathione. Urinary and faecal excretion occurs in 48hours where in 80 -90% 
of the compound is eliminated.(7).Most of the agents show some symptoms and 
signs within six to ten hours(8) with the exception of fat soluble compounds where 
it may take several days  to weeks to manifest because the substance must be 
leached out of the fat. Some opc have to be activated to active toxic state (hepatic 
activation of parathion to paraxon).Studies reveal that these residues may remain 
for days to week even after treatment.(8) 
HIGHLY TOXIC 
FOLIDOL, DIMECRON, TRITHION, CELATHION, SYSTOX 
MODERATELY TOXIC 
 BAYTEX, TIC20, ABATE, FINIT (9) 
LOW TOXIC  
MALATHION, DICHLORVOS (10) 
LIPHOPHILIC 
TRITHION, BAYTEX, FENTHION 
MECHANISM OF ACTION 
Acetylcholine (ACh) is the neurotransmitter released at all postganglionic 
parasympathetic nerve endings and at the synapses of both sympathetic and 
parasympathetic ganglia. It is also released at the skeletal muscle myoneural 
junction, and serves as a neurotransmitter in the central nervous system. ACh is 
hydrolyzed by acetyl cholinesterase into two fragments: acetic acid and choline. 
Acetyl cholinesterase is present in two forms: True acetyl cholinesterase 
which is found primarily in the tissues and erythrocytes, and pseudo cholinesterase 
which is found in the serum and liver. 
Organophosphorous compounds are acid-transferring inhibitors of 
cholinesterase. They cause cholinesterase to become firmly (and sometimes 
irreversibly) phosphorylated. This means that the action of cholinesterase will be 
inhibited. Cleavage of the carbon-enzyme bond from ACh is complete in a few 
microseconds. However, the breaking of the phosphorus-enzyme bond requires a 
period varying from 60 minutes to several weeks, depending on the 
organophosphorous compound involved. 
Reactivation of the inhibited enzyme may occur spontaneously. The rate of 
reactivation will depend on the species, the tissue, and the chemical group attached 
to the enzyme. Reactivation may be enhanced by hydrolysis of the acid-radical-
enzyme through the use of oximes (i.e. reactivating agents). Response  to 
reactivating agent's declines with time; this process being caused by "ageing" of 
the inhibited enzyme. Ageing is probably the result of the loss of one alkyl or 
alkoxy group, leaving a much more stable acetyl cholinesterase. The aged 
phosphorylated enzyme cannot be reactivated by oximes. 
Accumulation of acetylcholine causes over stimulation of both muscarinic 
and nicotinic receptors, and subsequently disrupts the transmission of nerve 
impulses in both the peripheral and central nervous system. (11) 
 
 Most of these opc do not possess a positive charge, hence they react with 
esteratic site but not with anionic site. Splitting of the acid group the occurs.                                       
The bond between phosphorous and esteratic site (free site) is more stable 
than the bond between carbon atom of acetyl choline and the same site. Thus 
blocking of the active site and consequent inactivation of enzymes results in 
accumulation of acetylcholine at cholinergic sites .Pseudo cholinesterase is a less 
specialized enzyme as it lacks an anionic site in a position that specially adapts it 
to react with acetylcholine. It does however react with acetyl choline, albeit, more 
slowly and also with a wide range of other esters  
BIOLOGICAL INTERACTIONS OF OPC (12)  
 
 
 
 
 
 
 
 
 
 
 
Fig.2 
CLINICAL FEATURES 
 The clinical features depend upon the end points where sustained 
cholinergic stimulation takes place namely 
a. Post ganglionic parasympathetic hollow end organ (muscarinic) 
b. Sympathetic and parasympathetic ganglionic and somatic neuro muscular 
junction(nicotinic)    
c. Central nervous system affection(13) 
Following exposure to organophosphorous compounds, the toxic features 
are usually obvious within 30 minutes to 3 hours. This may be delayed in some 
cases depending on the rate and amount of systemic absorption. The majority of 
 P=O agent 
Alkylatio
n
GSSH 
Oxidatio
AChE
Neuropathy 
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Hydrolys
patients give a history of intentional or accidental ingestion of organophosphorous 
compounds. Toxicity is produced by the rapid absorption of the compound 
through the gastrointestinal, respiratory tracts and skin. 
The clinical symptoms and signs are non-specific and will depend on the 
specific agent, the quantity and the route of entry. Some patients present with 
vomiting, diarrhea and abdominal pain, whilst others may be unconscious on 
arrival at the hospital. A high index of suspicion is therefore needed to make an 
early diagnosis.   Early cases present predominantly with parasympathetic over-
activity, and a characteristic garlic smell. The end result may be a multi-system 
manifestation involving the gastrointestinal, respiratory, and cardiovascular and 
nervous systems, as well as involvement of skeletal muscle, other organs and 
metabolic effects such as hypo or hyperglycemia. Most fatalities occur within 24 
hours and those who recover usually do so within 10 days.  
CARDIAC MANIFESTATIONS 
The commonest cardiac manifestations following poisoning are hypotension 
(with warm, dilated peripheries), and bradycardia. Patients seldom present with 
tachycardia and hypertension due to predominant nicotinic receptor blockade. 
Cardiac manifestations are often the cause of serious complications and fatality. 
(14). 
 
Table 2. Symptoms and signs of organophosphorous poisoning 
Muscarinic receptors Nicotinic receptors Central receptors 
Cardiovascular 
• Bradycardia  
• Hypotension  
Respiratory 
• Rhinorrhoea  
• Bronchorrhoea  
• Bronchospasm  
• Cough  
Gastrointestinal 
• Nausea/vomiting  
• Increased 
salivation  
• Abdominal 
cramps  
• Diarrhea  
• Faecal 
incontinence  
Genitourinary 
• Urinary 
continence  
Eyes 
• Blurred vision  
• Increased 
lacrimation  
• Miosis  
Glands 
Cardiovascular  
• Tachycardia  
• Hypertension  
Musculoskeletal  
• Weakness  
• Fasciculation  
• Cramps  
• Paralysis  
General effects  
• Anxiety  
• Restlessness  
• Ataxia  
• Convulsions  
• Insomnia  
• Dysarthria  
• Tremors  
• Coma  
• Absent reflexes  
• Respiratory 
depression  
• Circulatory 
collapse  
• Excessive 
salivation  
The mechanism of cardiac toxicity is unclear and the following has been 
postulated: 
• A direct toxic effect on the myocardium  
• Over activity of cholinergic or nicotinic receptors causing hemodynamic 
alteration  
• Hypoxia  
• Acidosis  
• Electrolyte abnormalities  
• High dose atropine therapy (used as treatment for organophosphate 
poisoning).  
RESPIRATORY MANIFESTATIONS 
Respiratory manifestations of acute organophosphorous poisoning include 
bronchorrhoea, rhinorrhoea, bronchospasm and laryngeal spasm. This is due to the 
action of the organophosphate on muscarinic receptors. The integrity of the airway 
may be compromised by excessive secretions. The nicotinic effects lead to 
weakness and subsequent paralysis of respiratory and oropharyngeal muscles. This 
increases the likelihood of both airway obstruction and aspiration of gastric 
contents. Finally, central neurological depression may lead to respiratory arrest.  
GASTROINTESTINAL MANIFESTATIONS 
Symptoms resembling gastroenteritis such as vomiting, diarrhea and 
abdominal cramps are the first to occur after oral ingestion of an 
organophosphorous compound.  
NEUROLOGICAL MANIFESTATIONS 
A large number of patients, following acute exposure to 
organophosphorous compounds, require prolonged ventilatory support in the 
intensive care unit due to neuromuscular weakness. The neurological 
manifestations have therefore been a primary focus of interest. There has been an 
emphasis on reducing the incidence of neuro-muscular respiratory failure. Three 
different types of paralysis are recognized based largely on the time of occurrence 
and their differing path physiology: 
• Type I paralysis or acute paralysis  
• Type II paralysis or Intermediate syndrome  
• Type III paralysis or Organophosphate- induced delayed polyneuropathy  
Type I paralysis or acute paralysis is seen during the initial cholinergic phase. 
This is when large numbers of both muscarinic and nicotinic receptors are 
occupied by acetylcholine, leading to persistent depolarization at the 
neuromuscular junction. Clinical features include muscle fasciculation, cramps, 
twitching and weakness. At this stage the patient may require ventilatory support 
due to the weakness of the respiratory muscles leading to respiratory depression 
and arrest. 
Type II paralysis or Intermediate syndrome. This was first described in 1974 
by Wadia et al (14)as type II paralysis and subsequently termed "The Intermediate 
Syndrome" by Senanayake. This syndrome develops 24-96 hours after the 
poisoning. Following recovery from the acute cholinergic crisis, and before the 
expected onset of delayed neuropathy, some patients develop a state of muscle 
paralysis. The cardinal feature of the syndrome is muscle weakness affecting the 
proximal limb muscles and neck flexors. There is a relative sparing of the distal 
muscle group. One of the earliest manifestations in these patients is the inability to 
lift their head from the pillow (due to a marked weakness in neck flexion). This is 
a useful test to establish whether or not a patient is likely to develop respiratory 
muscle weakness. Of the cranial nerves, those supplying the extra-ocular muscles 
are mostly involved, with a lesser effect on VII and X. This syndrome persists for 
about 4-18 days and most patients will survive unless infection or cardiac 
arrhythmias complicate the course. 
Type III paralysis or organophosphate- induced delayed polyneuropathy 
(OPIDP) is a sensory-motor distal axonopathy that usually occurs after ingestion 
of large doses of an organophosphorous compound (15-17)The neuropathy 
presents as weakness and ataxia following a latent period of 2-4 weeks. Initial 
stimulation causes excitatory fasciculation, which then progresses to an inhibitory 
paralysis. The cardinal symptoms are distal weakness of the hands and feet. This is 
often preceded by calf pain, and in some cases, parasthesia of the distal part of the 
limbs. Delayed CNS signs include tremor, anxiety and coma.                              
OTHER EFFECTS OF OPC MAY INCLUDE 
• Neuropsychiatric effects: Impaired memory, confusion, irritability, 
lethargy, psychosis, and chronic organophosphate-induced 
Neuropsychiatric disorders have been reported. The mechanism is not 
proven.(18) 
• Extra pyramidal effects: These are characterized by dystonia, cogwheel 
rigidity, and parkinsonian features (basal ganglia impairment after recovery 
from acute toxicity). 
• Other neurological and/or psychological effects: Guillain-Barré–like 
syndrome and isolated bilateral recurrent laryngeal nerve palsy are 
possible.(19) 
• Ophthalmic effects: Optic neuropathy, retinal degeneration, defective 
vertical smooth pursuit, myopia, and miosis (due to direct ocular exposure 
to organophosphates) are possible. 
• Ears: Ototoxicity is also possible(20). 
MODIFIED DREISBACH’ CLINICAL CRITERIA – KARNIT(9) 
 GRADE I   -  Mild symptoms related to portal of entry. 
    Nausea, vomiting in case of ingestion  
Cough, burning sensation in the chest in case of 
inhalation Mild systemic symptoms like headache, 
dizziness, weakness  
 GRADE II - Moderate systemic intoxication  
    Abdominal pain, diarrhea in case of ingestion. 
Tightness in chest, difficulty in breathing in case of 
inhalation 
Salivation,lacrimation, sweating, papillary changes. 
Bradycardia, confusion, tremor, restlessness. 
 GRADE III - Severe systemic intoxication  
    Respiratory depression, generalized weakness  
    Cyanosis, peripheral circulatory failure,  
convulsions coma. 
DIAGNOSTIC CRITERIA (13) 
• INVESTIGATORY MODALITES: ESTIMATION OF 
CHOLINEESTERASE LEVELS:  Organophosphate (OP) toxicity is a 
clinical diagnosis. Confirmation of organophosphate poisoning is based on 
the measurement of cholinesterase activity; typically, these results are not 
readily available. Although RBC and plasma (pseudo) cholinesterase levels 
can both be used, RBC cholinesterase correlates better with CNS acetyl 
cholinesterase (AChE) and is, therefore, a more useful marker of 
organophosphate poisoning. 
o  Measurement of RBC and plasma cholinesterase levels prior to 
treatment with pralidoxime (2-PAM). Monitoring serial levels can be 
used to determine a response to therapy. 
o RBC AChE represents the AChE found on RBC membranes, similar 
to that found in neuronal tissue. Therefore, measurement more 
accurately reflects nervous system OP AChE inhibition. 
o Plasma cholinesterase is a liver acute-phase protein that circulates in 
the blood plasma. It is found in CNS white matter, the pancreas, and 
the heart. It can be affected by many factors, including pregnancy, 
infection, and medical illness. Additionally, a patient's levels can 
vary up to 50% with repeated testing. 
o RBC cholinesterase is the more accurate of the 2 measurements, but 
plasma cholinesterase is easier to assay and is more readily 
available. 
• Cholinesterase levels do not always correlate with severity of clinical 
illness. 
• The level of cholinesterase activity is relative and is based on population 
estimates. Neonates and infants have baseline levels that are lower than 
adults. Because most patients do not know their baseline level, the 
diagnosis can be confirmed by observing a progressive increase in the 
cholinesterase value until the values plateau over time. 
• Falsely depressed levels of erythrocyte cholinesterase can be found in 
pernicious anemia, hemoglobinopathies, use of antimalarial drugs, and 
oxalate blood tubes. 
• Falsely depressed levels of plasma cholinesterase are observed in liver 
dysfunction, low-protein conditions, neoplasia, hypersensitivity reactions, 
use of certain drugs (succinylcholine, codeine, and morphine), pregnancy, 
and genetic deficiencies. 
• Other laboratory findings include leukocytosis, hemoconcentration, 
metabolic acidosis, hyperglycemia, hypokalemia, and hypomagnesemia. 
IMAGING STUDIES  
A chest radiograph may reveal pulmonary edema but typically adds little to 
the clinical management of a poisoned patient. Electrocardiographic 
manifestations include prolonged Q-Tc intervals, elevation of the ST segment, 
inverted T waves and a prolonged PR interval. There may also be rhythm 
abnormalities such as sinus bradycardia, ventricular extra- systoles, ventricular 
tachycardia and fibrillation. Ludomirsky et al described three phases of cardiac 
toxicity following organophosphate poisoning: 
• Phase I: A brief period of increased sympathetic tone  
• Phase II: A prolonged period of parasympathetic activity including AV 
node blockade  
• Phase III: Q-T prolongation followed by torsades de pointes, ventricular 
tachycardia and ventricular fibrillation (35) 
THERAPEUTIC CONSIDERATIONS 
Medical Care: Airway control and adequate oxygenation are paramount in 
organophosphate (OP) poisonings. Intubations may be necessary in cases of 
respiratory distress due to laryngospasm, bronchospasm, bronchorrhoea, or 
seizures. Immediate aggressive use of atropine may eliminate the need for 
intubation.(21) Succinylcholine should be avoided because it is degraded by acetyl 
cholinesterase (AChE) and may result in prolonged paralysis. 
• Continuous cardiac monitoring and pulse oximetry should be established; 
an ECG should be performed. Torsades de Pointes should be treated in the 
standard manner. The use of intravenous magnesium sulfate has been 
reported as beneficial for organophosphate toxicity.(22) The mechanism of 
action may involve acetylcholine antagonism or ventricular membrane 
stabilization. 
• Remove all clothing and gently cleanse patients suspected of 
organophosphate exposure with soap and water because organophosphates 
are hydrolyzed readily in aqueous solutions with a high pH. Consider 
clothing hazardous waste and discard accordingly. 
• Health care providers must avoid contaminating themselves while handling 
patients. Use personal protective equipment, such as neoprene or nitrile 
gloves and gowns, when decontaminating patients because hydrocarbons 
can penetrate non polar substances such as latex and vinyl. Use charcoal 
cartridge masks for respiratory protection when decontaminating patients 
who are significantly contaminated. 
• Irrigate the eyes of patients who have ocular exposure using isotonic 
sodium  
If ingestion occurred within 30 to 60minutes placement of nasogastric tube 
and administration of activated charcoal in a dose, 1g/kg orally. Cathartics are 
contraindicated because of electrolyte imbalance. (23)   
 Atropine administration: 3-5mg rapid intravenous should be given to reach 
effective atropinisation. The adequate atropinisation is gauged by five parameters. 
 1. Pulse rate >85/min 
 2. Systolic blood pressure >80mmHg 
 3. Absence of lung crepitations 
 4. Dry axilla 
 5. No constricted pupils(9) 
Then after three to five minutes if the parameters are not attained double the 
initial dosing. Atropine should be given in doubling dose pattern till adequate 
atropinisation. 
 
 Maintenance of atropinisation: 10 -20% of the bolus dose should be given 
as infusion in100ml normal saline and the parameters are assessed every 
15minutes.If there is inadequate atropinisation superimposed bolus in the dosage 
of 3-5mg should be given. Atropine should be tailored down hourly for six hours 
and then every two to three hours for the next 24hrs.Meticulous watch for atropine 
toxicity such as agitation, confusion, retention of bladder, hyperthermia, ileus and 
tachycardia should be done.    
OXIMES: PRALIDOXIME (2-PAM OR PROTO PAM) (24) 
Cholinesterase reactivation 
Oximes are nucleophilic agents that re-activate the phosphorylated acetyl 
cholinesterase by binding to the organophosphorous molecule. The use of oximes 
in acute organophosphorous poisoning has been a controversial subject for the last 
two decades as there have been very few randomized controlled trials that have 
addressed the role of pralidoxime (PAM). 
Pralidoxime has three main actions 
• A direct reaction converting the organophosphate to a harmless compound.  
• A transient reaction protecting the enzyme from further inhibition.  
• Reactivation of the inhibited alkyl phosphorylated enzyme to free the active 
unit (if given early enough)  
The reactivating action of pralidoxime is most marked at the nicotinic 
skeletal neuromuscular junction. It does not reverse the muscarinic manifestations 
of organophosphorous poisoning. Pralidoxime should be started as early as 
possible to prevent permanent binding of the organophosphate to acetyl 
cholinesterase. Once this has occurred, receptor regeneration is required to allow 
recovery. The recommended dose of pralidoxime in organophosphorous poisoning 
is 1 gram, by intravenous injection, every 6-12 hour in adults (maximum dose 
12g/24 hours) and 25-50mg/kg in children. Pralidoxime should be continued until 
adequate spontaneous ventilation is achieved by the patient. The effective plasma 
concentration is 4mg/litre and the patient should show signs of improvement 10- 
40 minutes after its administration. Plasma and pseudo cholinesterase levels 
should ideally be monitored during treatment. Side effects of pralidoxime include 
drowsiness, visual disturbances, nausea, tachycardia and muscle weakness, so 
treatment should be reserved for potentially fatal cases.  
PREVENTION AND EDUCATION 
Improved regulation of the availability of pesticides, strict regulation of 
vendors, and modifications in packaging of pesticides may all help reduce the use 
of organophosphates as poisons. Adequate provision of information to the public, 
regular training of health care providers, better availability of drugs / antidotes and 
the establishment of poison information centers will facilitate in reducing the 
morbidity and mortality related to organophosphorous poisoning. Insecticides 
should be kept out of reach of children, to prevent accidental poisoning. During 
agricultural spraying, proper precautions should be taken to prevent inhalation and 
accidental ingestion of the substance. The greatest incidence of 
organophosphorous poisoning was reported from Japan where there were 19,436 
cases over a period of 17 years (1953-1969).WHO used data from 19 countries 
and reported approximately5, 00,000cases of pesticide poisoning annually. Of 
these 99% belong to third world countries(24).In1981 the estimate was 75,000 
cases annually and rose to 3million in 1983 and majority were under the age of 
30(36).   Pesticide poisoning contributes more than forty percent of cases in 
Poison Centre GGH Chennai. The mortality rate due  to this poison is 42.29% 
(case register2001-2004). The victims are farmers of rural South India. Since only 
limited studies are available in analyzing the predictors of mortality in this most 
common form of agricultural poison, the outcome analysis of the predictors form 
the basis of the thesis  
OBJECTIVES 
1. To describe the epidemiology of organophosphorous poisoning in poison 
centre  Government General Hospital Chennai. 
2. To study the clinical profile of organophosphorous poisoning in poison 
centre  Government General Hospital Chennai                                                                            
3. To analyze the epidemiological and clinical factors in correlation to 
severity and outcome of organophosphorous poisoning in poison centre 
Government General Hospital Chennai. 
4. To identify prognostic indicators from biochemical parameters (renal 
function test, liver enzymes, arterial blood gas analysis, enzymes such as 
creatine kinase, creatine kinase mb fraction, serum amylase and lactate 
dehydrogenase,) to predict the severity, outcome and the need of ventilatory 
support. 
5. To asses the clinical severity and outcome of organophosphorous poisoning 
and correlate the same with pseudo cholinesterase levels 
6. To do outcome analysis of clinical  and biochemical parameters in 
mechanically ventilated patients . 
7. To compare the effectiveness of low dose versus high dose administration 
of  pralidoxime in organophosphorous poisoning in relation to the need of 
ventilatory support  and mortality. 
 MATERIALS AND METHOD 
SETTING: This study was conducted in the Poison centre GGH Chennai in 
collaboration of Institute of Internal Medicine and Institute of Biochemistry. It was 
a cross sectional prospective study done during the period from September2005- 
September2006. 87patients with history and clinical features suggestive of 
organophosphorous poisoning were selected irrespective of age and sex. 46 age 
and sex matched controls from normal population (patient attendants) were studied 
for biochemical markers.   
EXCLUSION CRITERIA 
1. Patients with other pesticide poisoning were excluded (eg., organo 
carbamate organochlorous compounds) by clinical features and  confirmed 
by  thin layer chromatographic analysis of gastric aspirate. 
2. Patients with other poisoning such as oleander, oduvanthazai , and drug 
over dosage(nicotine replacements, inocybe clitocybe, pilocarpine, 
opioids,phenothiazines,bethanechol.etc )known to mimic the clinical 
picture of organophosphorous poisoning were excluded. 
3. Patients with known medical illness such as neuromuscular disorders like 
myasthenia gravis or muscular dystrophy, hypokalemic periodic paralysis 
and conditions known to alter biochemical parameters were excluded. 
• Patients with known history of exposure to organophosphorous compounds 
were taken into consideration. The reliability on exposure was reinforced 
by definite history from the patients and their attendants. The container 
from which the poison where consumed were studied for the type and the 
quantity estimated. Each patient registered for the study went through 
detailed clinical evaluation as per the proforma.The cases were divided into 
three groups as mild moderate and severe by modified DREISBACH 
criteria. All patients underwent baseline laboratory investigations. The 
gastric aspirate was analyzed by thin layer chromatography method for the 
detection of poison. 
All patients underwent renal function test, arterial blood gas analysis, ecg  
chest roentogram and sonogram of the abdomen. 
 Serum AChE were measured on day 1 3 and 5.   
  The other biochemical markers such as liver enzymes, CK,CK-MB,LDH 
and amylase were taken on day1. 
BI0CHEMICAL MARKERS AND THE METHODS EMPLOYED- (KITS) 
1.CHOLINESTERASE - KINETIC COLOIMETRIC 
METHOD(26) 
2.SGOT (AST)   - UV KINETIC METHOD (27) 
3.SGPT                                       - (MODIFIED IFCC METHOD)- (28) 
4.ALKALINE PHOSPHATASE  - PNPP METHOD(29) 
 
5.ALBUMIN                           - BCG METHOD(30) 
6. CK                                        - UV KINETIC METHOD(31) 
7.AMYLASE                            - CNP – G3  METHOD(32) 
8. LDH                                        - UV KINETIC METHOD(28) 
On treatment aspect, average total dose of atropine administered per patient 
was calculated in mg. All patients  in  the study were given pralidoxime . They 
were sub divided into two groups –low dose and high dose based upon the total 
grams per day(<4gm/dayand >4gm /day)(33) 
• Ventilatory support was considered in patients with following 
parameteres   
a. RR >35/min  
 b. Apnea or obvious hypoventilation 
 c. Persistent cyanosis,excessive secretions,depressed level  pf 
unconsciousness,inability to protect the air way(34) 
d. PaO2          <  60 mmHg, FiO2  >0.6 
 PaCO2         >  50 mmHg, pH     <7.2 
 Mechanical ventilation was performed with  assist control mode and simv 
either as volume or pressure control. Positive end expiratory pressure was titrated 
to keep SaO2 above 94% with 40% FIO2. Weaning was performed using either T-
tube trials or pressure support weaning. All patients were monitored meticulously 
and vital signs assessed  till the outcome.   
STATISTICAL METHOD 
  The chi-square test was used for statistical analysis. Logistic Regression 
analysis was run to identify the parameters that would predict the clinical severity, 
need for mechanical ventilation and the outcome.   Data are presented as mean ± 
standard deviation. 
Detailed evaluation of each patient  was made. Each variable  in the pro-
forma was correlated with  severity and  mortality.  
RESULTS 
Epidemiological Pattern  of  OPC in Poison Centre, Govt. General Hospital 
TABLE 3 - Age Distribution 
Sl.No. Age Group in years Frequency(n) Percentage 
1. <= 20 17 19.54 
2. 21-30 40 45.98 
3. 31-40 15 17.24 
4. > 40 15 17.24 
 Total 87 100.00 
 
 Majority of the patients  were in the  21 to 30 age group. The number of 
people between the age group 20 to 40 accounts for 55  out of 87  cases.  
TABLE 4 – Age Distribution and Outcome 
Sl.No. Age Group in years Outcome 
Discharge            Death 
1. <= 20 14 3 
2. 21-30 33 7 
3. 31-40 10 5 
4. > 40 8 7 
 Total 65 22 
 
 The correlation between  the age group and the outcome was not 
statistically  significant (P value – 0.11) 
Table.5 Sex Distribution 
Sl.No. Sex Frequency(n) Percentage 
1. Male  76 87.36 
2. Female  11 12.64 
 
Incidence of OPC  was more in males when compared to females in our 
series.  
Table.6 - Occupation 
Sl.No. Occupation Frequency(n) Percentage Expired 
1. Agriculture 40 45.98 9 
2. Unskilled Labour 37 42.53 9 
3. Others  10 11.49 4 
 
 More than 80 percent of the cases of OP poisoning were among  
agriculturalists and unskilled labourers. The death rate was also more among these 
groups.  
 
Locality – Distance  from the Poison Centre, Govt. General Hospital in Kilo 
Meters. 
Table 7 – Locality  
Sl.No. Locality (kms) Frequency(n) Percentage 
1. <= 100            40 45.98 
2. > 100             47 54.02 
 
Table 8 - Type of Poison consumed 
Sl.No. Type of Poison consumed (kms) Frequency(n) Percentage 
1. CHLORPYIFOS 6 6.90   
2. DIMECRON 26 29.89 
3. QUINALPHOS (EKALUX)     3 3.45 
4. FENTHION (BAYTEX)        2 3.45 
5. HINOXAN 3 2.30 
6. MALATHION 
(CHEMATHION)       
2 2.30 
7. METHYL PARATHION 
(METAPHOS) 
1 1.15 
8. MONOCROTOPHOS 2 2.30 
9. PARATHION (FOLIDOL, 
EKATOX) 
30 34.49 
10. PHORATE 3 3.45 
11. SYSTOX 1 1.15 
12. TRIPHOS 6 6.90 
 Total  87 100.00 
 
 Most of the patients  in this series  consumed  parathion (n=30) and 
Dimecron (n=26).  But the type of poison  does not contribute  both to severity and 
mortality.  
Table.9 - Route Of Exposure 
Sl.No. Route of Exposure Frequency(n) Percentage 
1. Ingestional 75 86.2 
2. Inhalational 10 11.5 
3. Topical 2 2.3 
 
 Ingestional exposure was more common among in the series(86.2%) and 
most of the patients in this entity fell under the severe grade  of Dreisbach’s 
criteria (P value = 0.03).  
Intention Of Poison: Suicidal (75) - Accidental (12) 
Table.10 Duration of stay in hospitals 
Sl.No. Duration of Stay in 
Hospitals (in days) 
Frequency(n) Percentage 
1.       <= 5                  38 43.68 
2. 6-10 32 36.78 
3. > 10 17 19.54 
  87 100.00 
 
 The mean duration of stay in the hospital is  7.25 days (SD 4.64)   
Table 11 - Duration Of Hospital Stay  Correlation With Clinical Severity-  
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 In this series of 87 cases, more severe grade of intoxication had  longer  
duration of stay in the hospital (P value =0.0002) 
Table 12 -  Quantum  of exposure 
Sl.No. Quantity consumed (ml.) Frequency(n) Percentage 
1.                 NA  25 28.74 
2. <=50  29 33.33 
3. 51-100 19 21.84 
4. >100 14 16.09 
 Total 87 100.00 
 
 The non availability of data in 25 patients was due to two reasons. 1. 12 
cases had inhalataional and topical forms of exposure so the quantity cannot be 
ascertained 2. In 13 cases reliable information regarding  the quantity of 
consumption was not known. The average quantity of consumption in this series 
amounts to 101.58ml.  
Table 13 – Quantity  of Consumption and Clinical Severity 
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 Patients who have consumed more than 100 ml. of OPC have higher grade 
of severity (P value = 0.004).  The quantity consumed had  no relation to the 
mortality rate. 21 cases had OPC mixed with alcohol. Two cases consumed OPC 
mixed with phenol and kerosene. 
 
 Table.14 - Onset Of Symptoms After Exposure 
Sl.No. Time of onset of 
Poisoning (Mins.) 
Frequency(n) Percentage 
1. NA 1 1.15 
2. <=30 40 45.98 
3. 31-60 36 41.38 
4. >60 10 11.49 
 Total 87 100.00 
 
 Most of the patients  had their  initial symptom  of intoxication between 30 
minutes to one hour.   
PERIOD INTERVAL FOR INITIATION OF TREATMENT  
a) Initiation of First Aid (Gastric Lavage/activated charcoal) 
Table 15 –Initiation Of First Aid 
Sl.No. Initiation of First aid 
(Hours.) 
Frequency(n) Percentage 
1. <=1 33 37.93 
2. 1-2 32 36.78 
3. >2 22 25.29 
 Total 87 100.00 
 
 Out of 87 patients 65 received first aid either at household or nearby 
medical facility within two hours.  
  
b) Initiation of Atropine  
Table.16 - Time of initiation of Atropine 
Sl.No. Time of initiation of 
Atropine  (Hours.) 
Frequency(n) Percentage 
1. <=1 35 35.63 
2. 1-3 38 43.68 
3. >3 18 20.69 
 Total 87 100.00 
 
c) Initiation of 2- PAM  
Table 17 - Time Of Initiation Of 2-PAM 
Sl.No. Time of initiation of 
2-P AM  (Hours.) 
Frequency(n) Percentage 
1. NA 4 4.60 
2. <=1 27 31.03 
3. 1-3 36 41.38 
4. >3 20 22.99 
 Total 87 100.00 
 
 More than  60 percent of  the cases in this series have reached nearest 
medical services within three hours  to receive their initial doses of  atropine and 2 
PAM. 
Time taken to reach poison centre from the time of consumption 
Table 18 - Time taken to reach Poison Centre 
Sl.No. Time taken to reach Poison 
Centre, GGH (Hours.) 
Frequency(n) Percentage 
1. NA 2 2.30 
2. <=5 30 34.48 
3. 6-10 29 33.33 
4. >10 26 29.89 
 Total 87 100.00 
 
 The mean  duration to reach poison centre from the time of consumption - 
9.99 hours.  
Table 19 - Time interval to reach Poison Centre and Clinical Severity 
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 65 cases in the series were referred cases from other medical services. 
Patients reaching poison centre more than six hours  after consumption came 
under severe grade of poisoning (P value = 0.02).  The  time  interval between  
initiation of first aid atropine and P2 AM did not have statistically significant 
correlation with outcome.  
SYMPTOM ANALYSIS    
 60 cases in the study presented with  gastro intestinal symptoms (68 %) 
such as  nausea,  vomiting,  cramps and  diarrhoea. 47 cases had central Nervous 
system manifestations, out of which 26 presented with type 1 paralysis, 13 had  
seizures and 8 had IMS/Type 2 paralysis. Two cases with IMS had VII AND X  
cranial nerve affection.  27 cases had both GIT and nervous symptoms. Two cases 
presented predominantly with cardiac  symptoms of chest pain and palpitations.      
Table 20 - Cases  Grouped According To Dreisbach Clinical  Criteria At 
Admission 
Sl.No. Mild  Moderate  Severe  
1. 15 
(17.2%)
29 
(33.3%) 
43 
(49.4%) 
 
In  this series of 87 cases,   49.4% of patients  belong  to the  severe grade 
of poisoning.  
 
1.  Severity grading (Dreisbach clinical  Criteria) correlation with outcome 
Table 21- Severity Grading and outcome 
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 The mortality rate in the severe group was 41.9%. The correlation between 
severity grading and  mortality as a very high statistical significance (P value 
=0.002) 
2. Severity grading (Dreisbach clinical  Criteria) correlation to the need of  
ventilatory support 
Table 22 - Severity Grading and Ventilatory Management 
Ventilatory Management   
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 Out of  42 cases on mechanical ventilation, 39 cases were initiated on assist 
control mode and three were put on synchronized intermittent mandatory 
ventilation. (SIMV)  
PROXIMAL MUSCLE GROUP INVOLVEMENT IN OPC 
 47 out of 87 cases had involvement of proximal muscles such as neck 
flexors, bulbar muscles and muscles of the shoulder and  pelvic griddle.  Out of  
this group, 8 cases developed IMS. The correlation of proximal muscle group 
affection was studied in relation to  clinical severity, outcome and the need of 
mechanical  ventilation.    These three variables studied had statistically significant 
relationship.  
Table 23 -  Proximal Muscle Group Involvement and Clinical Severity 
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 33 cases of proximal muscle group involvement had severe grade of 
poisoning.  
Table 24 - Proximal Muscle Group Involvement and Ventilatory 
Management 
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Table 25 - Proximal Muscle Group Involvement and Outcome 
Outcome  
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 The mortality rate among the  group which had proximal  muscle  
involvement   was 34 percent.  
LABORATORY PARAMETERS  
1. Average hemoglobin observed in these  series – 13.2 g/dl/(SD =2.40)  
2. Total WBC count had a range between 6500 and  27000 cells per cubic 
mm. and it had a mean value -14,038(S.D-5233.3) 
3.  Routine Bio-chemistry  
Table 26 – Bio Chemistry Values 
Sl.No. Values Mean S.D. (+/-) 
1. Blood Sugar mg/dl. 103.7 32.26 
2. Urea mg/dl. 27.92 13.22 
3. Creatinine |0.91 0.27 
4. Sodium 134 6.3 
5. Potassium 3.83 0.55 
6. Chloride 111.95 6.14 
 
4. Liver Function Test (These parameters did not have any correlation with 
severity and outcome. The values of  87 patients  are given below: 
Table 27 - LFT 
Sl.No. Values Mean S.D. (+/-) 
1. SGOT  IU/L 52.89 22.55 
2. SGPT  IU/L 47.23 27.23 
3. Total Protein g/dl 6.54 0.48 
4. Albumin  g/dl 3.60 0.70 
5. SAP IU/L 152.4 69.4 
 5. Arterial blood gas analysis  
Table 28 - ABG 
Sl.No. Values Mean S.D. (+/-) 
1. ph 7.33 0.14 
2. PaCo2 mm/hg 43.31 13.17 
3. PaO2 87.05 16.28 
4. O2Sat 90.99 14.30 
5. Bicarbonate 23.44 5.58 
 
Interpretation of arterial blood gas analysis  revealed that 51 patients  had  
normal pH. 28 patients had metabolic  acidosis and 8 had respiratory  alkalosis. 
The arterial blood gas analysis was studied in relation to severity of poisoning, 
need of ventilatory support of outcome. The results are as follows:  
Table 29 – ABG & Clinical Severity 
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Table 30 – ABG & Ventilatory Support 
Ventilatory Support 
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Table 31 – ABG  & Outcome 
Outcome  
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The three variables namely, clinical severity, need of ventilatory support 
and the outcome had statistically significant  correlation with pH. 
5. ECG changes are classified into three groups (35)  
ECG with normal limits n=22 
Phase 1GROUP -    n=43 
Phase 2 GROUP     n=18    
Phase 3 GROUP     n= 4  
Out of 18  in phase 2 group of ECG changes seven needed ventilatory 
support and the morality rate was 33.34%(n=6).All the four cases in phase3  group 
needed ventilatory support and every one recovered. 
6. Gastric aspirate analysis by Thin layer chromatography in detection of 
OPC.  
  In this series out of 75 cases of ingestional form of exposure the TLC 
method detection rate was 84 percent.  
7. Pseudocholinesterase  Levels in OP Poisoned Patients  
Table 32 - Pseudocholinesterase  Levels in OPC poisoned Patients 
Serum 
CHe Level 
IU/L 
N Mean SD Minimum 
Value 
Maximum 
Value 
Range
Day 1 87 841.32 1426.7 31.00 7000.0 6969.0
Day 3 87 1301.7 1697.4 48.00 7259.0 7211.0
Day 5 87 1664.3 1965.7 50.00 7259.0 7840.0
 
The mean level of  Serum CHe among the age and  sex matched control 
population (n=46) is 7090 IU per litre. The total number of 87  patients were 
classified  on the basis of  serum CHe level in the  following manner :  
1. Mild (20 to  50% of 7090)  
2. Moderate (10 to 20%  of 7090) and  
3. Severe (Less than 10%)  
In these  series, Day 1  CHe estimation  correlated  well with  Dreishbach  
clinical criteria of severity but it has no statistically significant relationship to 
predict the need of mechanical ventilation and outcome. 
Table 33 – Day 1 Serum AcHE Level & Clinical Severity 
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Day 3 and  day 5 serum CHes estimation had significant and very 
significant statistical  relationship respectively with three variables of clinical  
severity, to predict the need of mechanical ventilation and  outcome. 
Table 34 - Day 3 Serum AcHE Level & Clinical Severity 
Clinical Severity  
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Table 35- Day 3 Serum AcHE Level & Ventilatory Support 
Ventilatory Support 
                      No support       Assist Control Mode     
SIMV Mode  
N
or
m
al
  
(>
50
%
) n=10 
100% 
n=0 
 
n=0 
 
M
ild
  
(2
0 
to
 
50
%
) n=8 
57.1%  | 
n=6 
42.9% 
n=0 
 
M
od
er
at
e 
 
(1
0 
to
 
20
%
) 
n=11 
73.3% 
n=4 
26.7% 
 
n=0 
 
D
ay
 3
 S
er
um
 C
H
e 
Le
ve
l a
s %
 o
f N
or
m
al
  
Se
ve
r
e 
 
(<
10
n=16 
33.3%  | 
n=29 
60.4% 
n=3 
6.3% 
                         (P value = 0.00311) 
Table 36 - Day 3 Serum AcHE Level & Outcome 
Outcome  
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Table 37 -Day 5 Serum AcHE Level & Clinical Severity 
Clinical Severity  
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Table 38 - Day 5 Serum AcHE Level & Ventilatory Support 
Ventilatory Support 
 No support             Assist Control             
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Table 39 - Day 5 Serum AcHE Level & Outcome 
Outcome  
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Table 40 - Creatine kinase (CK) and its MB Fraction (CKMB) 
Sl.No. Values Normal Mean S.D. (+/-) 
1. CPK IU/L 15-130 723.20 827.75 
2. CPK MB IU/L 0-24 100.33 112.73 
           (P Value = 0.0000) 
 Both the enzymes level elevation in the cases of OP Compound poisoning  
were statistically significant.  
 
 Both serum CK  and  CK MB fraction  elevation  correlated very well with 
clinical severity grading and the need of mechanical  ventilation. There is no 
statistical significant  relationship between these enzymes elevation and the 
outcome.  
Table 41 - Serum CK Level & Clinical Severity 
Clinical Severity  
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Table 42 - Serum CK Level & Ventilatory Support 
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Table 43 - Serum CKMB Level & Clinical Severity 
Clinical Severity  
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Table 44 - Serum CKMB   Level & Ventilatory Support 
Se
ru m
Ventilatory Support 
 No support      Assist Control     SIMV  
N
or
m
al
  
 
n=14 
87.5% 
n=2 
12.5% 
n=0 
 
A
bn
or
m
al
  n=31 
43.7%  | 
n=37 
52.1% 
n=3 
4.2% 
                          (P value = 0.00642) 
SERUM AMYLASE   
 In all 87 cases, serum amylase and ultra sonogram of the abdomen were 
done. Sonography of the abdomen were normal in all cases.  The mean  serum 
amylase level in the series 110 U/L.  The rise of serum amylase levels was directly 
related to  the severity and the need of mechanical  ventilation.  
Table 45 - Serum amylase Level & Clinical Severity 
Clinical Severity  
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Table 46 - Serum Amylase    Level & Ventilatory Support 
Ventilatory Support 
 No support            Assist Control                 
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SERUM LDH    
 The mean LDH level in the series – 540 U/L (SD- (+/-) 247.02) 
 The Serum LDH elevation in cases of  OPC poisoning  was  highly 
significant (P value = 0.0000).  The LDH elevation did not have any correlation 
with clinical severity, need of  mechanical ventilation and the outcome.   
 
TREATMENT CONTRIBUTES  
In our series of 87 patients  mean atropine  requirement: 268.51mg 
(S.D179.96) 2PAM was given to all patients. They were grouped in a non random 
fashion into two groups as low dose and high dose on basis of total dose given per 
day.(<4gm/day and >4gm/day). Average mean requirement of  2PAM - 31.64gm 
(SD 18.62|)36 patients came under the low dose group and 51 patients in the high 
dose group. These groups were   compared in relation to severity, need of 
ventilatory support and outcome and their correlation was statistically significant. 
Table 47 - 2PAM & Clinical Features 
Clinical Features  
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Table 48 - 2PAM & Ventilatory Support 
Ventilatory Support  
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Table 49 - 2PAM & Outcome 
Outcome  
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VENTILATORY SUPPORT 
Out of 87 patients 42 needed ventilatory support.(48.27%).39 patients were 
initiated on assist control mode and three were started on simv mode. 
 The average duration of mechanical ventilation in the series was  
7.11days (S.D= 4.53) .The more the severe grade of poisoning  more was the need 
of mechanical ventilation.(pvalue=0.0000).19 out of 42 cases on mechanical 
ventilaton expired .The morality rate among patients on mechanical ventilation 
was 45.23%. Their correlation was very significant. The mortality rate differed 
with patients with ventilatory support and with that of no support (6.7%).  The 
difference  was  statistically significant.  
Table 50 - Ventilatory Support & Outcome 
 Ventilatory Support No Support 
No.of Patients  42 45 
Recovered  23 42 
Expired  19 3 
 (P Value =0.001) 
All the 8 cases of  IMS (type2 )syndrome were on mechanical ventilation.The 
mean duration of these cases on mechanical ventilation-17.5 days. One case 
expired and seven got discharged.Eight cases needed tracheostomy during 
mechanical ventilation and three cases out of them had type2paralysis. 
Outcome  In this series 22 expired. The mortality rate was  25.29%. In 18 
cases primary cause of death was  respiratory failure with secondary cardiac arrest. 
It has resulted from central respiratory depression, respiratory muscle weakness, 
increased bronchial secretions, broncho spasm and acute pulmonary oedema.4 
cases developed torsades de pointes and they expired due to ventricular 
fibrillation.19 out of 22 cases needed ventilatory support. 
LOGISTIC REGRESSION ANALYSIS 
in order to identify important variables that would predict the need of mechanical 
ventilation and outcome  this stastical method was adopted. 
 a. Need for ventilatory support  
Dependant variable – ventilatory support. 
Independent variables- 1.Duration of hospital stay 
 2. Clinical severity grading 
 3. Proximal muscle affection 
                                                  4.Creatine kinase (CK) 
 5.Total dose of atropine(mg) 
 6.Day 1serum AcHE level  
                                                            7.Total dose of 2PAM 
 The correlation was found out to be very significant (p=0.0000) by chi 
square test. The prediction percentage was high as 96.55%. 
 INFERENCES: Variables with  positivity were clinical severity,total dose 
of atropine and total dose of 2PAM, ie more the clinical grade of severity, greater 
the dose of atropine and 2PAM  the need for mechanical ventilation was high. 
 Variables with negativity were duration of hospital stay, proximal muscle 
affection, day1 serum ChE and creatine kinase (i.e.) shorter the hospital stay, non 
involvement of proximal muscle group, lesser inhibition  of day 1 serum che and 
low creatine kinase the need for ventilatory support was low. 
B PREDICTORS OF.OUTCOME 
Dependant variable-Outcome  
Independent variables   1.Duration of hospital stay 
     2.Clinical severity grading 
                                            3. Proximal muscle affection 
                                                       4.Creatine kinase (CK)  
5.Day 1serum AcHE level 
6.Day 5serum AcHE level 
7. Total dose of atropine 
8.Total dose of 2PAM  
9.Ventilatory support.                                                                       
 The correlation was found out to be very significant(p=0.0000) by chi 
square test. The prediction percentage was 87.36%. 
 INFERENCE: Patients with severe poisoning (driesch bach criteria), 
elevated levels of creatine kinase,   more the total dose of  atropine , greater 
reduction of day 1 che levels were associated with significant mortality. 
 In the series, patients with shorter duration of stay in the 
hospital,noninvolvement of proximal muscles, lesser inhibition of day 5 che levels 
and lower the dose of  total p2am administered were associated with good 
outcome,. 
DISCUSSION 
Comprehensive analysis of 87 cases of acute organophosphorous poisoning 
EPIDEMIOLOGY OF ORGANOPHOSPHOROUS POISONING:  
Age Pattern. 
In this series the opc poisoning was prevalent in the 21-30 age 
group.57cases were below the age of 30.WHO has reported about 3million cases 
of opc exposureand40,000deaths annually  and majority were under the age group 
of thirty. (36) Murat Sungur and Muhammed Güven et al of TURKEY observed 
the mean age group of opc exposure was 30±15 years.(12) Karalliedde L, 
Senanayake N.et al of SRILANKA documented 91% of their cases were under 
the age of 30.(37). In Kashmir valley Malik et al.  revealed that 33.5% of the 
cases of opc were under the age of 25.(38) In Mangalore, Karnataka, India  the 
most common age group to be affected was between     20-30 (36.6%)  (36). The 
series reported in this thesis   had the similar pattern of age group affection. The 
reason could be that this age group by all probability is vulnerable to various 
emotional conflicts that occur during this phase of life. This young age group 
affected by exposure form the viable entity of any population both in terms of 
procurement and productivity. This case study and the case reports mentioned 
above throw light on the target age group for educative and preventive 
programmes to reduce the incidence of opc poisoning.       
 
SEX DISTRIBUTION  
 In poison centre  GGH Chennai males were exposed more when compared 
to female population.(87.36% versus 12.64%). On the contrary to the series in 
Murat Sungur  study  of 47 cases of opc in Turkey(12) [(female n=25, 
male=22)]and. Malik et al.  observation of 122 cases in Kashmir valley[(female 
n=114,male=50)]  female intoxication was more. In Srilanka and Mangalore had  
similar pattern  to  the case series of the poison centre.(male 86%-female 
14%).S.Shivakumar and K.Raghavan et al of Tamil Nadu reported 165 cases of  
organo phosphorous poisoning and sex distribution was similar to the case series 
(male n=122, female n=45)(39).This variation was due to handling of poison by 
the respective sex in their respective locality. In Kashmir the female population 
are predominantly employed in apple orchards and they are involved in pesticide 
control. In southern part of India males are actively involved in spraying fertilizers 
and pesticides. 
OCCUPATION AND SOCIOECONOMIC STATUS  
Wesselling C, McConnell R, Partanen T, Hogstedt C et al reported that 
large worker populations in the Third World were exposed to increasing amounts 
of pesticides, including pesticides severely restricted and banned in industrialized 
countries. Studies on knowledge, attitudes, and practices indicate that unsafe use 
of pesticides was the rule in Third World countries.(40).In our case series  77out 
of 87 cases were agriculturists and unskilled labourers.54.02% of the cases were 
from rural areas.(n=47).The mortality rate were also high among the these group. 
In Kashmir valley two third of the population who had exposure were  engaged in 
apple orchard.In  Karnataka agriculturists formed the majority.Students formed the 
predominant group in Nepal (41) whereas in Almeria exposure was more in green 
house workers.(42). 
INTENTION OF POISON. 
Estimates from the WHO indicate that each year, 1 million accidental 
poisonings and 2 million suicide attempts involving pesticides occur 
worldwide. (10). In the series majority of cases were suicidal in nature 
which was consistent with other workers.75cases(86.21%) were suicidal and 
12 cases(13.79%) had accidental exposure. 
Murat Sungur and Muhammed Güven et al observed 68%of opc 
poisoning reported were of suicidal exposure and  Karalliedde L, 
Senanayake N et al of SRILANKA had similar pattern. Malik et al. reported 
74.4% of cases were of suicidal in nature and rest(25.6%) had accidental 
exposure. Palimar Vikram MD, Arun M MD, DNB et al in their case study 
of 153 cases in Mangalore reported 98.7%of sucidal exposure. Most of the 
agriculturists consume for the fact of failure of crops, increasing debts 
coupled with the easy availability of poison. 
 2700 people are referred to hospital for self poisoning each week in the 
United Kingdom alone. It is likely to be even more difficult for the developing 
world, with its limited resources, to address this problem effectively. However, we 
think that the time has come to acknowledge the seriousness of the situation as a 
first step towards preventing this massive unnecessary loss of life.(43) 
 
ROUTE OF EXPOSURE: 
Ingestion of the opc poisoing (n=75) formed th majority in this series apart 
of inhalational(n=10) and topical (n=2) form of exposure. 
In the series most cases of grade III severity were ingested OPC but the 
correlation with the outcome was not significant. The mortality rate in the 
ingestional group-26.7% Arup Kumar Kundu, JD Mukhopadhyay, AK Saha, S 
Das et al(44)studied 108patients in sub urban West bengal poison.90 consumed 
the poison and the death rate was12% and it had positive correlation with 
outcome. In Kashmir Valley out of 164 cases-ingestional route(n=140), 
inhalational (n=7) and topical exposure(n=17). In the Turkey study the 
gastrointestinal route was the main route in 44 (93.6%) patients. 
TYPE OF POISON 
 In this study parathion(34.49%) and dimecron(29.89) were the most 
common type of poison consumed when compared to other workers. The type of 
poison did not contribute much to the severity and mortality. 
Murat Sungurb et al in TURKEY observed the three common type of opc were:  
Agent Number of patients
Dichlorvos 24 (51.1%) 
Ethyl-Parathion 5 (10.6%) 
Fenthion 4 (8.5% 
 
In sub urban West Bengal Arup kumar kundu et al showed that mortality was high 
in poisoning with monocrotophos and dimethoate (31%) and nil with malathion. In  
the Mangalore study methyl parathion was the most common poison consumed. 
Karalliedde L, Senanayake N. reported dimethoate, methamidophos, malathion, 
monocrotophos and fenthion as the common type opc consumed in Srilanka. In the 
Kashmir valley phosphamidon(55%), malathion(12%) and dichlorovas(8.5%) 
were the commonly used opc compounds for ingestion.In study from Tamil nadu  
S.Shiva Kumar and K.Raghavan et al of Tamil Nadu reported methyl parathion as 
the most common form of exposure in their study group. 
In this case series the severity of poison was directly proportional to 
quantity consumed. (pvalue=0.004).There was no relation to mortality. But the 
study from West Bengal  showed there was a correlation between the quantity 
consumed and the mortality.  
CLINICAL CONTRIBUTES  
 In this case study, the average  duration between  the onset of   symptoms 
and consumption was 44.73 (SD 26.76). Dr.Sumathi Joshi et.al. reported that  the 
symptoms of  OPC poisoning developed  between 30 minutes and  1 hour (45). In 
this study group, patient  reaching the  Poison centre by more than 6 hours  had 
grade 3 severity (P value 0.02). More than 60 per cent of the cases have the 
accessibility to have their first aid, first doses of  atropine and 2PAM before  3 
hours. But these  variables  did not have  significant  correlation with  the  
outcome. But the West  Bengal workers  reported  increased  mortality among the 
patients  who had  increased  time interval before initial  atrophinazation (44).    In 
this  series,  presenting muscuranic symptom predominantly involved the GIT  
(68%) followed by the central nervous system manifestations.  Murat Sungurb et 
al in Turkey reported that the CNS symptoms  such as depressed mental status, 
confusion and muscle  weakness were the common  presentation.  Kenneth D.Ketz 
et.al. from Pittsburg reported neuro psychiatric manifestations, ototoxity,    
Guillain-Barré (46) –like syndrome and isolated bilateral recurrent laryngeal nerve 
palsy in OPC poisoning. In this series, there were two cases with lower cranial 
involvement, one with bilateral LMN type of facial palsy and the other with tenth 
cranial nerve affection.   
CLINICAL SEVERITY (MODIFIED DREISHBACH CRITERIA)  
 In this case series, most of  the patients admitted  fell into the  grade 3 
group of  clinical severity (n=43) 49.4%. The reason  could be  that this centre 
being a referral unit, complicated  cases, warranting specialist  treatment, intensive 
care  monitoring, ventilatory support (n=65) were  transferred from primary health 
centres, district hospitals and private nursing homes.  Arup Kumar Kundu (et.al) 
reported, mild 15 (14%), moderate 55 (50.9%), and severe 32 (29.6%) in his  
study  based on OPC poisoning in  sub-urban West Bengal.   In that study, the  
severe  grade of poisoning was associated with   increased  ventilatory support and 
poor outcome. Similarly, in this case series, clinical  severity  association with 
need of  ventilatory  support and  mortality was  statistically significant (P value = 
0.002).   
In this case study, proximal muscle  group  affection formed an important  
parameter to assess the  need of ventilatory support, progression to grade 3 
severity and  predictor  of outcome.   
LAB CONTRIBUTES  
        In this study group, the average total WBC count 14,038 cells cubic mm. 
(SD. 5233). Leucocytosis were also reported in the studies from Turkey and 
Pittsburg. The liver function tests observed in this study had similar pattern of 
mild elevation when compared to the study from Murat Sungurb et al in 
TURKEY. The arterial blood gas  analysis performed in this study had  significant 
correlation with severity, outcome and the need of ventilatory support similar to 
the observations made by A.Goe, S.Joseph, et.al.(47). Kenneth D. Ketz, et.al. who 
documented metabolic acidosis in his  study group.  
ECG  
        Most of the cases in this  series had sinus tachycardia (n=43) 18 cases had 
AV nodal inhibition and 4 cases had QTC prolongation  followed by torsade de 
pointes, ventricular tachycardia and ventricular fibrillation. Patients with  phase 2 
and   phase 3  ecg changes  as described by Ludomirsky et al. (25)  were 
associated with grade 3 severity   and outcome similar to observations made by 
Dalvi, CP, et.al.(48).        
CHOLINESTERASE LEVELS AND ITS SIGNIFICANCE  
        In this  case  study, day 1 Che  correlated very well with clinical criteria of 
dreishbach    (P value = 0.001).    This     finding    was   also   observed by Bobba 
R, Venkataraman,   BV, Pais P, Joseph T. et.al. in Bangalore (49). In contrary to 
this  observation, S.N. Chugh and Navneeth Agarwal, et.al. found no relationship 
between serum CHE  estimation and severity  grading (50).  In this case series, 
logistic regression analysis was  run to predict the  outcome  in which day 1 and 
day 5 CHE level were important parameters. Sequential post exposure estimations 
of the ChEs upto 5 days not reveal any rise in the values though there was 
substantial clinical improvement. This observation was in par with the study in 
Bangalore (49).  Day 3 and day 5 ChE levels in this study had statistically 
significant  association with need of ventilatory support. 
 SERUM AMYLASE 
In all 87 patients serum amylase and  ultra sonogram of the abdomen was 
performed in order to  identify transient pancreatits which is a rare complication 
(51). Ultra sonography  of the abdomen  was done in all the cases.  Serum 
Amylase  elevation was statistically significant.  4 cases out of 87,  had serum 
amylase  level > 300  U/L out of which two cases  expired.  Sahin I,  Onbasi K,  
Sahin H, Karakaya C, Ustun Y, Noyan T. et.al. observed 4 out of  47 cases  in 
their  series, had amylase  elevation more than 300 U/L.(52). Lee WC, Yang CC, 
Deng JF, Wu ML, Ger J, Lin HC, Chang FY, Lee SD, et.at. stated that : 
hyperamylasemia was frequent in severe organophosphate poisoning. However, 
hyperamylasemia was not synonymous with acute pancreatitis and pancreatic 
amylase was not a reliable parameter in the diagnosis of organophosphate-induced 
pancreatitis due to its low sensitivity and specificity (53).  In this series of  87 
patients in Poison centre  serum amylase level  was directly related to clinical 
severity and the need of ventilatory support (P value < 0.001). This observation 
was also documented in the Taiwan study (53).  
SERUM LDH  
 Serum LDH elevation denotes  oxidative damage done to skeletal muscles 
during OPC. (55). In this series, mean LDH levels were 540.53 U/L (SD 247.02)  
and the elevation was significant.  Murat Sungur and Muhammed Güven of 
Turkey observed mean LDH levels of 548.8 ± 45.5 U/L. Sahin I,  Onbasi K,  
Sahin H, Karakaya C, Ustun Y, Noyan T. et.al. also found out LDH  levels to be 
elevated. But in this series,  LDH did not have any correlation with clinical 
severity, outcome nor to the need of ventilatory support.   
CK AND CK MB 
    In this series, both enzyme level elevation were  significant. CK rise  may 
indicate skeletal muscle  injury due to sustained  stimulation of  acetylcholine at 
the  neuro muscular junction. The MB fraction of CK suggest myocardial 
dysfunction due to primary effect of OPC compounds on the heart as well as 
overzealous administration of atropine. Both CK and CK MB elevation were able 
to predict the clinical severity and  the need of ventilatory support but not in 
outcome  assessment. John M, Oommen A, Zachariah A. et.al. studied  the 
correlation between  muscle  injury and Type 1/Type 2 paralysis  with enzymes 
markers in OPC  poisoning and made similar observations  (54).  
TREATMENT CONTRIBUTES 
 The average total dose of atropine administered  in the case series, 268.51 
mg  (SD 179.96) Murat Sungur and Muhammed Güven of Turkey study of 47 
patients their  average   total dose of atropine was 79.1 ± 62.9 mg. S.N. Chugh and 
Navneeth Agarwal, et.al. observed the average total dose  for atropine 248 ± 
196mg.  
In this series,  2PAM was given to all patients.They were grouped in a non 
random fashion into two groups as low dose and high dose on basis of total dose 
given per day.(<4gm/day and >4gm/day). Average mean requirement of  2PAM - 
31.64gm (SD 18.62)came under the low dose group and 51 patients in the high 
dose group.   The grade of clinical  severity, the need of ventilatory support and 
the mortality were more among the high dose  group when compared to the  low 
dose  administration of  2PAM.  Arun Kumar  Kundu, et.al. in a study in sub-
urban  West Bengal related high dose  2PAM administered in first 24 hours  was  
associated with  adverse outcome (44). In 1991, De Silva studied the treatment of 
organophosphate poisoning with atropine and 2-PAM and, later the same year, 
with atropine alone. He found that atropine seemed to be as effective as atropine 
plus 2-PAM in the treatment of acute organophosphate poisoning. The controversy 
continued when other authors observed more respiratory complications and higher 
mortality rates with use of high-dose 2-PAM. Low-dose (1-2 g slow IV) 2-PAM is 
the current recommendation. Studies are underway to assess the role of low-dose 
2-PAM (39) A recent meta-analysis performed by Peter et al (2006) revealed that 
oxime therapy was associated with a ”null effect or possible harm” in terms of 
organophosphate poisoning (56). Johnson S, Peter JV, Thomas K, Jeyaseelan L, 
Cherian AM. et.al. in their double blinded randomized control study revealed high 
dose  2PAM group were associated with risk of intermediate  syndrome, longer  
duration of ventilation and increased mortality rate (39) S.Shivakumar and K. 
Raghavan, et.al. compared the effectiveness of  high dose 2PAM with  low dose 
by selection of patients in non-random  manner.  They  found  out  the high dose  
2PAM group had better  survival, lesser incidence of type 2 paralysis and 
shortened  duration of  ventilation.  
 
VENTILATORY SUPPORT 
Out of 87 patients 42 needed ventilatory support.(48.27%).39 patients were 
initiated on assist control mode and three were started on simv mode.19 out of 42 
cases on mechanical ventilaton expired. The morality rate among patients on 
mechanical ventilation was 45.23%.  The difference in mortality between the 
ventilatory and the non-ventilatory was  significant (P value 0.00013) 
The average duration of  mechanical  ventilation in the series  was  
7.11days (SD = 4.53).  Grade 3 clinical severity, proximal muscle affection, 
elevation of  creatinine Kinase, low values of day 1 serum ChE and higher  dose of  
2PAM were  the predictors for the need of  mechanical  ventilation.  Murat Sungur 
and Muhammed Güven of Turkey  in the study of 47 patients  of OPC reported  
Mechanical ventilatory support was needed for 10 (21.2%) patients The duration 
of mechanical ventilation was 4.1 ± 3.2 days. The mortality rate for the patients 
who were mechanically ventilated was 50% (5 patients), although the mortality 
rate was 27.6% (13 patients) for all patients. The mortality rate for the 
mechanically ventilated patients was not statistically different compared with 
those patients not mechanically ventilated. Two patients who are mechanically 
ventilated died with sudden cardiorespiratory arrest following ventricular 
tachycardia, and three died from pneumonia and complicating adult respiratory 
distress syndrome S.Shivakumar and K. Raghavan, et.al. in their  case  series of 
165 patients 22 to patients were mechanical ventilated, out of which 14 died.  
OUTCOME ANALYSIS  
 In this series 22 expired. The mortality rate was  25.29%. In 18 cases 
primary cause of death was  respiratory failure with secondary cardiac arrest. It 
has resulted from central respiratory depression, respiratory muscle weakness, 
increased bronchial secretions, broncho spasm and acute pulmonary oedema.4 
cases developed torsades de pointes and they expired due to ventricular 
fibrillation.19 out of 22 cases needed ventilatory support. By statistical method of 
logistic regression, the following parameters predict the outcome. The prolonged 
duration of  hospital  stay grade 3 clinical  severity, proximal muscle involvement, 
suppressed  day 1 and day 5 ChE levels, elevated  creatine kinase, high dose of 
2PAM and mechanical  ventilation were associated with poor outcome.  
Karalliedde L, Senanayake N. et.al. reported  mortality rate of  18% in their study 
of 92 cases of OPC in Sri Lanka.  Arup Kumar Kundu, JD Mukhopadhyay, AK 
Saha, S Das  Burdwan Medical College and Hospital, Burdwan, West Bengal 
analysed  that increased time interval before initial atropinisation, higher clinical 
grading, respiratory paralysis at the time of admission, higher quantity of poison 
consumed, type of poison (e.g., monocrotophos and dimethoate), poison ingested 
rather than inhaled, development of encephalopathy and/or is ECG changes (pulse 
rate < 45/min, complete heart block QT-prolongation), and higher dosage of PAM 
used in first 24 hours were  associated with  increased  mortality.  In Kashmir 
valley a study of  164 patients of  OPC poisoning, the mortality rate  was 5.5%.  In 
the Mangalore  study,  the mortality  was 26.2%. Murat Sungur and Muhammed 
Güven of Turkey reported  the mortality rate of 32%.  
CONCLUSIONS 
¾ Organophosphorous poisoning is most prevalent in the 21-30 age 
group.Incidence is more common in males . 
¾ Organophosphorous poisoning is more common among agricultural 
labourers and unskilled workers. 
¾ The most important cause for consumption of organophosphorous poison is 
self harm. 
¾ The common route of exposure is ingestion of poison and it is associated 
with clinical severity.(p<.0.05). 
¾ The quantity consumed has direct proportional relationship with severity of  
poisoning(p<0.01). 
¾ The duration of stay in the hospital has significant correlation with clinical 
severity(p<0.01) 
¾ The higher the  clinical grade of poisoning at initial presentation more the 
need of ventilatory support(p<0.01) and adverse the outcome(p<0.01) 
¾ The proximal muscle involvement in organophosphorous poisoning forms 
an important indicator in assessment of clinical severity(p<0.01),need of 
ventilatory support(p<0.01) and the outcome.(p<0.05). 
¾ The day one serum cholinesterase level can be used as a  diagnostic marker 
and a tool to gauge the clinical severity.(P<0.01). 
¾ The day three and day five serum cholinesterase level estimation has a 
strong prognostic value in assessment for the need of ventilatory 
support(p<0.01)and outcome(p<0.01). 
¾ The blood gas analysis forms an important investigation in 
organophosphorous poisoning in correlation with clinical 
severity(p<0.01),prediction of ventilatory support(p<0.01) and the 
outcome.(p<0.01) 
¾ Serum creatine kinase and lactate dehydrogenase elevation are significant 
in organophosphorous poisoning(p<0.01).They reflect skeletal muscle 
injury and oxidative stress caused by the poison. 
¾ Serum creatine kinase and the MB fraction prove to be a prognostic indices 
in predicting the grade of clinical severity(p<0.01) and need of ventilatoy 
support(p<0.01). 
¾ Hyperamylasemia is frequent in severe organophosphate 
poisoning.(p<0.01) However, hyperamylasemia is not synonymous with 
acute pancreatitis of organophosphorous poisoniong.The enzyme elevation 
is directly related to severity(p<0.05) and predicts the need  of  ventilatory 
support.(p<0.01). 
 
 ¾ The need of ventilatory support and the duration of mechanical ventilation 
are more for the high dose pralidoxime group(p<0.01) when compared to 
the low dose group. Patients in the high dose pralidoxime group had 
adverse outcome.(p<0.01). 
¾ The following parameters predict the need of ventilatory support, grade 3 
clinical severity, proximal muscle affection, elevation of  creatine kinase, 
low values of day 1 serum cholinesterase and the high dose of  pralidoxime. 
The parameters were evolved by  statistical  method of logistic regression 
with predictive percent of 96.55%. 
¾ The following parameters predict the outcome. The prolonged duration of  
hospital  stay, grade 3 clinical  severity, proximal muscle involvement, 
suppressed  day 1 and day 5 ChE levels, elevated  creatine kinase, high 
dose of pralidoxime and mechanical  ventilation are associated with 
increased mortality. The parameters were evolved by  statistical  method of 
logistic regression with predictive percent of 87.36%. 
  
RECOMMENDATIONS AND AREAS OF FUTURE RESEARCH 
1. In the management of organophosphorous poisoning the role of oximes is 
challenged by many studies(57).Hence a large high-quality RCT comparing 
the current WHO-recommended regimen with placebo is required to 
definitively assess the value of pralidoxime in acute OP poisoning.   
2. Fresh frozen plasma therapy increases BuChE levels in patients with 
organophosphate poisonings. The administration of plasma may also 
prevent the development of intermediate syndrome and related mortality 
(58). Plasma (fresh frozen or freshly prepared) therapy may be used as an 
alternative or adjunctive treatment method in patients with 
organophosphate pesticide poisoning, especially in cases not given 
pralidoxime. Further randomized controlled are required to infer a 
definitive result. 
3. Magnesium sulfate administration to cases of organophosphorous 
poisoning  reduced  mortality rate and decreased the duration of stay in the 
hospital (22).The role of magnesium sulfate need to be studied in our 
Indian context.  
 
SUMMARY 
Organophosphorous poisoning is a menace to the human race   both as a 
weapon of mass destruction and a misused pesticide of self harm. The case fatality 
rate  exceed 60% in developing countries where there are many pit falls in 
treatment protocol and research activities. So a comprehensive analysis of  87 
patients of organophosphorous poisoning was done in Poison Centre  Government 
General hospital Chennai. 
All the cases included in the studied underwent detailed clinical evaluation 
and extensive laboratory work up.Each patient was monitored periodically till the 
outcome. 47 intensive care unit. There were 76 males and 22 female patients. The 
predominant age group was 21- 30years.75 patients were suicide attempts and 12 
had accidental exposure. 75 (86.2%) of the patients were poisoned through the 
gastrointestinal route. 10 (11.5%) patients had inhalational poisoning and two 
(2.3%) patients had topical exposure There were 12 different types of OP 
insecticide agents involved. The estimated average time for the admission to 
POISON CENTRE  after the exposure was 9.9hours. According to Dreisbach 
clinical criteria at admission, 49.4% of patients  belong  to the  severe grade of 
poisoning. 47 out of 87 cases had involvement of proximal muscles such as neck 
flexors, bulbar muscles and  muscles of the shoulder and  pelvic griddle. The 
blood gas analysis and serum cholinesterase levels had significant correlation with 
clinical severity,mechanical ventilation and outcome. Serum amylase, LDH, 
creatine kinase  and ck-mb elevation were significant. 
  The average total dose of  atropine was 268.51mg.All patients received 
pralidoxime.   The grade of clinical  severity, the need of ventilatory support and 
the mortality were more among the high dose   group when compared to the  low 
dose group of patients who received pralidoxime. Mechanical ventilatory support 
was needed for 42(48.27%) patients 
 The duration of mechanical ventilation was 7.11 ± 4.5days. The mortality 
rate for the patients who were mechanically ventilated was 45.23%(19 patients), 
although the mortality rate was 25.29% (22 patients) for all patients. The mortality 
rate for the mechanically ventilated patients was  statistically significant when 
compared with those patients not mechanically ventilated. The grade 3 clinical 
severity, proximal muscle affection, elevation of  creatine  kinase, low values of 
day 1 serum cholinesterase and the high dose of  pralidoxime predicted the need of 
ventilatory support.  
 The predictors of adverse outcome were prolonged duration of  hospital  
stay, grade 3 clinical  severity, proximal muscle involvement, suppressed  day 1 
and day 5  levels serum cholinesterase ,elevated  creatine kinase, high dose of  
pralidoxime and mechanical  ventilation. 
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PROFOMA    -    COMPREHENSIVE ANALYSIS OF 
ORGANOPHOSPHOROUS POISONING 
                                   
 
NAME :                         AGE:                         SEX:       OCCUPATION: 
 
LOCALITY:                        D.O.A                       D.O.D            
 
 
DURATION OF STAY  : MORTALITY: 
 
 
HISTORY 
 
 
TYPE OF POISON 
 
 
ROUTE OF EXPOSURE    INGESTIONAL    TOPICAL   INHALATIONAL 
 
 
QUANTITY 
 
 
TIME OF ONSET OF POISONING 
 
 
TIME OF INITISATION OF FIRST AID (LAVAGE ACTIVATED 
CHARCOAL) 
 
 
TIME OF INITIATION of ATROPINE 
 
 
TIME OF INITIATION of P2 AM 
 
 
TIME TAKEN TO REACH HOSPITAL 
 
 
ASSOCIATED POISONING 
ASSOCIATED ALCOHOL INTAKE 
 
SYMPTOMATOLOGY  
 
INTENTION OF THE POISON:       Suicidal  Accidental    Homicidal 
 
 
CLINICAL CONTRIBUTES  MILD        No Symptoms; Normal vitals 
              Normal pupils 
  
         MODERATE    
Fasciculation; Perspiration 
    Pupillary changes; Tachypnoea; 
    Early pulmonary edema 
 
SEVERE      
Pin point pupil, frank Pulm-edema ,     
Respiratory paralysis,   Unconciousness 
 
PROXIMAL MUSCLE WEAKNESS: 
 
 
 BULBAR MUSCLE WEAKNESS: 
 
 NECK WEAKNESS: 
 
 
 IMS SYNDROME 
 
 ASSOCIATED CLINICAL FINDINGS: 
 
 
 LAB CONTRIBUTES 
 
 
HEMOGRAM : HB       TC           DC                            ESR            PCV          
 
 RFT   Urea Creatinine  Na+       k+      hco3     Cl-  
 
SUGAR           : 
 
ABG :                                        CXR:     USG ABDOMEN: 
 
 ECG: ST-T CHANGES QTC PROLONGATION 
  LOW VOLTAGE  PROGRESSIVE LOSS OF VOLTAGE 
 
GASTRIC ASPIRATE                                       
 
SERUM PSEUDO CHOLINEESTRASE LEVELS 
       DAY1 
       DAY2 
       DAY3 
 
 CPK           CPK MB   
 LFT :   SGPT         SGOT          SAP        TB                       
 LDH          AMYLASE      
  
TREATMENT CONTRIBUTES 
 
 TOTAL DOSE OF ATROPINE 
 
TOTAL DOSE OF P2 AM ( Less than 4 gms per day | More than 4 gms per day) 
 
 
ANTIBIOTICS:TYPE                      DURATION           
 
VENTILATORY  SUPPORT: INTIATIONMODE:                 
 
DURATION :       
 
 OUTCOME 
 
 MORTALITY RATE 
 
 CAUSE OF DEATH 
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 Fig.11 Correlation of Serum Cholinesterase levels with Clinical grading 
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 KEY 
 
Sex                                  :       Male    = 1                    Female  = 2 
Occupation                    :       Agriculturist   = 1      Unskilled workers      = 2             Others  = 3 
Locality                          :       <100 km = 1                >100 km =2 
Intention                        :        Suicide = 1                Accidental      = 2 
Association poison     :       Yes = 1  No = 2 
Alcohol Intake               :       Yes = 1   No=2 
Severity                          :       Mild = 1                Moderate = 2           Severe = 3 
Proximal muscle Involvement : Yes = 1     No.2 
ECG                                 :       1= PI   2=PII     3 = PIII       4 = Normal       5 = Sinus Bradycardia 
Ventilatory support     :        1=Nil           2=Assist Control           3 =Simv 
Outcome                        :        1=Discharge    2 = Death 
